MAIT cells come to the rescue in cancer immunotherapy? by Łukasik, Zuzanna et al.
 Cancers 2020, 12, 413; doi:10.3390/cancers12020413 www.mdpi.com/journal/cancers 
Review 
MAIT Cells Come to the Rescue in  
Cancer Immunotherapy? 
Zuzanna Lukasik 1,2, Dirk Elewaut 1,2 and Koen Venken 1,2,* 
1 Department of Internal Medicine and Pediatrics (Rheumatology Unit), Faculty of Medicine and Health 
Sciences, Ghent University, 9000 Ghent, Belgium; zuzanna.lukasik@stud.umed.lodz.pl (Z.L.); 
dirk.elewaut@ugent.be (D.E.) 
2 Molecular Immunology and Inflammation Unit, VIB Center of Inflammatory Research,  
9052 Ghent, Belgium 
* Correspondence: Koen.venken@ugent.be 
Received: 7 January 2020; Accepted: 7 February 2020; Published: 11 February 2020 
Abstract: Recent progress in immunobiology has led to the observation that, among cells classically 
categorized as the typical representatives of the adaptive immune system, i.e., T cells, some possess 
the phenotype of innate cells. Invariant T cells are characterized by T cell receptors recognizing a 
limited range of non-peptide antigens, presented only in the context of particular molecules. 
Mucosal-associated invariant T cells (MAIT cells) are an example of such unconventional cells. In 
humans, they constitute between 1% and 8% of the peripheral blood T lymphocytes and are further 
enriched in mucosal tissues, mesenteric lymph nodes, and liver, where they can account for even 
40% of all the T cells. MAIT cells recognize antigens in the context of major histocompatibility 
complex class I-related protein (MR1). Upon activation, they instantly release pro-inflammatory 
cytokines and mediate cytolytic function towards bacterially infected cells. As such, they have been 
a rapidly evolving research topic not only in the field of infectious diseases but also in the context 
of many chronic inflammatory diseases and, more recently, in immuno-oncology. Novel findings 
suggest that MAIT cells function could also be modulated by endogenous ligands and drugs, 
making them an attractive target for therapeutic approaches. In this review, we summarize the 
current understanding of MAIT cell biology, their role in health and disease and discuss their future 
potential in cancer immunotherapy. This is discussed through the prism of knowledge and 
experiences with invariant natural killer T cells (iNKT)—another prominent unconventional T cell 
subset that shares many features with MAIT cells. 
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1. Untangling the Riddle of MAIT Cells’ Biology 
The characteristic feature of innate-like T cells are subtype-specific semi-invariant T-cell 
receptors (TCR) interacting with particular antigen-presenting molecules and recognizing non-
peptide antigens. Mucosal-associated invariant T cells (MAIT) cells display a semi-invariant α-chain 
of the TCR (Vα7.2-Jα33/20/12 in humans and Vα19 in mice) combined with a limited repertoire of 
TCR-β chains, predominantly from TRBV6 and TRBV20 gene families [1] (Figure 1). Their antigen 
recognition is restricted to non-peptide molecules presented in the context of non-polymorphic major 
histocompatibility complex (MHC) class I-like protein MR1 [2]. These antigens include vitamin B 
metabolites synthetized by a range of microorganisms. Vitamin B metabolism pathways are highly 
conserved across species, and therefore antigen presentation in the context of MR1 molecule allows 
for the recognition of a group of pathogens upon their shared metabolic signature [3]. Furthermore, 
MR1 restricted antigens are bound and presented without host–cell processing [4]. Several immune 
cell types, including monocytes, dendritic cells, and B cells express MR1 molecules. The default 
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extracellular expression of MR1 is very low—in the absence of their ligands, MR1 molecules are 
mostly maintained in an unfolded conformation in the endoplasmic reticulum [5,6]. Antigen binding 
results in a transient relocation of MR1 molecules to the cell surface, as, within hours from antigen 
presentation, they become internalized again [7]. Moreover, surface expression of MR1 is upregulated 
under inflammatory conditions. Interestingly, functional MR1 expression was found on several 
cancer cell types [8,9]. 
This observation is particularly interesting in the context of thymic MAIT cell development. It 
was shown that MAIT cells are selected by interaction with MR1-expressing thymocytes but not 
thymic epithelial cells nor thymus-resident immune cells [1,10]. The selection is maintained in germ-
free bred mice, suggesting possible existence of endogenous MR1 ligands [2]. MAIT cells egress from 
thymus displaying a naïve phenotype and as such are present in low numbers in cord blood. After 
birth, they acquire a memory, an innate-like phenotype, and expand into the peripheral blood and 
the mucosal tissues. This process is dependent on a timely sequence of events: intra-thymic induction 
of a tissue-residency program [11], commensal flora colonization [2], and priming by MR1-expressing 
antigen-presenting cells [12]. In the absence of commensal microbes and in B-cell deficient subjects, 
naïve MAIT cells fail to mature and expand, and the entire population diminishes [1]. These findings 
on MAIT cells’ peripheral maturation and expansion are further supported by the fact that these cells 
are more abundantly present in the peripheral blood than in the thymus at any age of individual 
development. The number of circulating MAIT cells increases steadily in the first three decades of 
life and then decreases gradually [13]. Knowledge on age-dependent fluctuations in MAIT cell 
frequencies in mucosal tissues is currently lacking. 
MAIT cells were first discovered and characterized as a double negative (DN) CD4-CD8- T cell 
population abundant in the peripheral blood of healthy subjects and expressing an invariant TCR α 
chain and the CD161 surface marker [14]. These markers initially served for identification and further 
phenotyping of human MAIT cells. From these studies, it was clear that MAIT cells express CD26, 
CD44, CD69, and CD25 surface molecules as well as cytokine receptors such as interleukin 7 receptor 
(IL-7R), IL-12R, IL-15R, and IL-18R and transcription factors PLZF (promyelocytic leukaemia zinc 
finger), RORγt (RAR-related orphan receptor gamma), and T-bet (T-box transcription factor) [15]. 
Closer analysis of the expression of CD4 and CD8 co-receptors on human peripheral blood MAIT 
cells revealed that, in fact, the majority of them were CD8+CD4-. Only about 14% of the peripheral 
blood MAIT cells were double-negative. In addition, a minor subset of these cells was described as 
CD4+CD8− single positive or CD4+CD8+ double-positive [16]. It was revealed that these subsets 
differentially decline with age, suggesting further variances in the regulation of their development 
[16]. The functional role of CD4 and CD8 co-receptors in MAIT cells biology remains to be elucidated, 
but distinct patterns of cytokine production were noticed between the subsets [17]. Studies in mice 
showed clear polarization between IL-17A- and interferon y (IFNγ)-producing sub-lineages, 
expressing transcription factors RORγt and T-bet, respectively. MAIT17 development was recently 
found to be strongly dependent on TCR signals received in the thymus, with this subset being hugely 
decreased in germ-free mice. Upon colonization, thymic expansion and maturation of MAIT17 cells 
was observed, with no changes in MAIT1 cell numbers [18]. The latest research confirms that the 
bifurcation into MAIT1 and MAIT17 subtypes occurs within the thymus and reveals further factors 
contributing to MAIT cell maturation and differentiation [19,20]. In contrast to mice, no clear partition 
into MAIT1 and MAIT17 subtypes is observed in human MAIT cells, which are also potent producers 
of tumor necrosis factor α (TNFα). 
Functional studies revealed that different MR1 ligands may induce distinct effects on MAIT cells. 
Riboflavin (vitamin B2)-derivatives were observed to potently activate MAIT cells [21], while folate 
(vitamin B9)-derived antigens do not seem to do so. Riboflavin derivatives bound by MR1 are 
pyrimidine adducts of its unstable precursor, 5-Amino-6-D-Ribitylaminouraci (5-A-RU). These 
compounds are generated by most of the Prokaryotes and Fungi but not in animals devoid of the 
riboflavin biosynthesis pathway [22]. Interestingly, certain pathogenic bacteria have lost the ability 
to synthesize riboflavin and have adapted to its exogenous uptake. These facts partially explain the 
dependence of MAIT cell development on timely commensal colonization and the changes in MAIT 
Cancers 2020, 12, 413 3 of 19 
 
cell activity observed in dysbiosis [23]. A small percentage of peripheral blood MAIT cells was 
discovered to be reactive towards the MR1 molecule itself [16]. The introduction of MR1-Ag tetramers 
[loaded with 5-(2-oxoethylideneamino)-6-D-ribitylaminouracil (5-OP-RU)] into the MAIT cell 
research was a breakthrough allowing for the recognition of distinct phenotypical and functional 
MAIT cell subsets [24,25]. Since human MAIT cells were initially identified upon TCRVα7.2 and 
CD161 markers, the abundance and the specific physiology of the described subsets in mucosal 
tissues and liver need further research by use of MR1 tetramer staining methods. 
Importantly, MAIT cells can be activated independently of their TCR stimulation. Due to their 
high expression of several cytokine and chemokine receptors (IL-18R and IL-12R in particular), they 
respond to mediators released by other immune cells during infection. The protective role of MAIT 
cells in viral infections is completely MR1 independent and mostly relies on IL-18 signaling (in 
synergy with other cytokines) [26]. Type I interferons provide a strong costimulatory signal, 
enhancing MAIT cell secretory activity [27]. The MAIT cell response to pathogens is intensified and 
fine-tuned by the type of antigen-presenting cells involved, immune checkpoints signaling and 
cytokine stimulation additional to MR1-bound antigen recognition [28]. Moreover, these 
costimulatory signals enable MAIT cell proliferation at the site of infection, which is not induced by 
TCR stimulation alone [29]. Inducible T-cell costimulator (ICOS), which is constitutively highly 
expressed on the surface of MAIT cells, and IL-23 were recently identified as crucial second signals 
[28]. 
Upon activation, MAIT cells robustly release perforin and granzymes and produce the pro-
inflammatory cytokines TNFα, IFNγ, and IL-17A as well as the potent granulocyte stimulation factor 
MIP-1. Production of other cytokines such as IL-22, IL-13, IL-26, or IL-2 was described in the context 
of different cytokine milieus and tissue subsets [29–32]. The rapid MAIT cell response to pathogenic 
bacteria is fully MR1-dependent [33], but the long-range activation is shaped by the combination and 
the amount of other stimuli [34,35]. Interestingly, IL-12 and IL-18 stimulation resulted in a dominant 
IFNγ production, while MR1 signaling was related to TNFα and IL-17A [33]. IL-7 triggered local 
proliferation and tissue accumulation of different IL-17-producing innate-like T cells, including 
MAIT cells [36]. The release of the aforementioned mediators results in destruction of infected cells 
and activation of other immune cell types [37]. This includes stimulation of dendritic cell maturation, 
which consequently leads to mobilization of natural killer (NK) cells and conventional T cells and 
evokes a cascade of immune events [38]. Recent transcriptomic analyses suggested that the role of 
MAIT cells in mucosal immunology expands beyond pathogenic microbes detection and also covers 
barrier maintenance [29,30]. MAIT cells exhibit transcriptomic signature associated with epithelial 
barrier integrity preservation, which was further upregulated during acute infection [29]. In-vitro 
stimulation of human MAIT cells with 5-OP-RU, akin to mouse MAIT cell activation by experimental 
bacterial infection (Legionella), resulted in striking upregulation of not only pro-inflammatory gene 
sets but also genes related to tissue repair (transforming growth factor beta-1, platelet derived growth 
factor subunit B and matrix metallopeptidase 25) and angiogenesis (granulocyte-macrophage colony-
stimulating factor, vascular endothelial growth factor, hypoxia inducible factor 1 subunit alpha) [29]. 
This finding is in line with increased gut permeability in Mr1 knockout mice [39] and was confirmed 
on a functional level by wound-healing assay experiments [30,40]. 
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Figure 1. Mucosal-associated invariant T cells (MAIT) cell biology. MAIT cells are the largest antigen-
specific T cell population in the human immune system. They recognize vitamin B-derived 
metabolites presented in the context of the major histocompatibility complex class I-like protein 
(MR1) molecule. MAIT cells develop in the thymus where they acquire tissue-homing properties in a 
three-stage process dependent on commensal microbiota and antigen-presenting cells. MAIT cells 
further mature in the periphery. Due to an array of cytokine and chemokine receptors, they respond 
to costimulatory signals provided by other immune cells and rapidly produce cytotoxic mediators, 
interferon gamma (IFNγ), tumor necrosis factor alpha (TNFα), and numerous interleukins. MAIT 
cells represent the innate-like branch of the immune system and, owing to their immediate, tailored-
to-factor activation, orchestrate the immune response.  
2. The Harmony of Invariant T Cells 
Studies on MAIT cell development and effector functions point towards their close relationship 
with another unconventional T cell population, the invariant natural killer T cells [41] (Table 1). 
Invariant natural killer T cells (iNKT) cells express a semi-invariant αβTCR (human Vα24/Jα18 
combined with Vβ11, mice Vα14–Jα18 combined with Vβ2, Vβ7, or Vβ8.2), which allows them to 
recognize lipid antigens presented by CD1d molecules [42]. Similar to MAIT cells, iNKT cells are 
capable of secreting large amounts of cytokines and chemokines upon activation in a TCR-dependent 
or a TCR-independent way [43]. Moreover, both unconventional T cell populations (and their 
subsets) share the expression of transcription factors T-bet, RORγt, and PLZF [44]. The expression of 
T-bet and RORγt is required for IFN-γ and IL-17 production, respectively. PLZF was found to 
regulate cell effector maturation and orchestrate expansion in non-lymphoid tissues, the 
characteristic feature of MAIT and iNKT cells [45]. Mucosal surfaces allow for further maturation and 
phenotype acquisition of both innate-like cell populations. In contrast to MAIT cells, however, the 
intrathymic development of iNKT cells is irrespective of commensal microbiota, as no changes in 
iNKT numbers are seen in germ-free bred mice [18]. Nevertheless, common gene products were 
found crucial for their intrathymic development, such as members of the signalling lymphocyte 
activation molecule (SLAM) family receptors [19]. This might reflect a developmental competition 
between MAIT and iNKT cells or/and indicate that the two invariant T cell populations share 
complementary immune functions. In line with this, it has been shown that CD1d-deficient (NKT 
cell-deficient) mice exhibit increased numbers of MAIT cells (and vice versa) [2]. However, despite 
vast interindividual differences in MAIT and iNKT cell abundance, the ratio of the two populations 
across human blood samples seems to be constant in health (and sometimes disease), suggesting they 
are also controlled by similar genetic and/or environmental factors, at least in the periphery [41,46,47]. 
Altogether, the multi-level resemblance leads to the idea that MAIT and iNKT cells are 
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complementarily bridging innate and adaptive immunity, and this interdependence is tightly 
regulated by common developmental or homeostatic factors while retaining their specific role in non-
peptide TCR mediated immune responses. 
Table 1. MAIT and invariant natural killer T cells (iNKT) cell characteristics and roles in 
malignancies. 
Feature MAIT Cells iNKT Cells Ref. 
TCR 
combinations 
Human: TRAV1-2–
TRAJ33 (pairs 
predominantly with 
TRBV20-1 or TRBV6 
(polyclonal); TRAJ12 and 
TRAJ20 have also been 
demonstrated 
Mice: Vα19 combined 
with Vβ6 or Vβ8  
Human: TRAV10–TRAJ18 
(invariant) pairs predominantly 
with TRBV25-1 (polyclonal) 
Mice: Vα14–Jα18 combined with 
Vβ2, Vβ7, or Vβ8.2 
 
[25,41] 
Prevalence in 
peripheral blood 
1–10% of T lymphocytes 
in peripheral blood of a 
healthy adult (mouse 
0.1%); increases until the 
3rd decade of life and 
then drops 
0.01–1% of T lymphocytes in 
peripheral blood of a healthy 
adult; decreases with age 
[13,48,49] 
Tissue frequency 
40–50% of intrahepatic T 
lymphocytes (in contrast, 
0.6% in mice) 
1–5% of lymphoid cells in 
the intestinal mucosa 
2% of skin T cells, mostly 
residing at the interface 
of dermis and epidermis 
1% of intrahepatic lymphocytes 
(in contrast 10–30% in mice) 
5% of lung-resident lymphocytes 
>15% of adipose tissue T cells 
 
[40,50–53] 
MHC restriction MR1 CD1d [48] 
Activating 
ligands 
Riboflavin intermediate 
metabolites (e.g., 5-OP-
RU and 5-OE-RU) 
Drug metabolites (e.g., 
diclofenac metabolites).  
Bacterial and synthetic 
glycol(sphingo)lipids and 
phospholipids (e.g., α- GalCer, β-
GlcCer, diacylglycerols, 
cholesteryl α-glucosides and 
ether-bonded mono-alkyl 
glycerophosphates) 
[7,54] 
Inhibiting 
antigens/ligands 
Folate derivatives (e.g., 6-
FP, Ac-6-FP), 
GM2 ganglioside, 
aminobisphosphonates 
[55,56] 
Cell markers and 
phenotype 
PLZF, RORγt, T-bet; 
IL-7R, IL-12R, IL-15R, IL-
18R; 
CD3, CD4, CD8, CD161, 
CD44, CD69, CD25; 
display an effector-
memory phenotype prior 
to antigen exposure, 
TCR-independent 
activation 
T-bet, GATA3, PLZF, RORγt; 
IL-12R, IL-18R, IL-27R; 
CD3, CD4, CD8, CD161, CD69, 
CD103, CRTAM; 
display an effector-memory 
phenotype prior to antigen 
exposure, TCR-independent 
activation 
[25,39,50,57] 
Subsets MAIT1, MAIT17 
NKT1, NKT2, NKT10 and 
NKT17; ability to further [19,50] 
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differentiate functionally under 
inflammatory conditions 
Role in solid 
tumors 
- ↓ of peripheral 
blood frequency 
- cytotoxicity towards 
malignant cells in 
experimental 
conditions 
- infiltrate tumor 
environment; 
express exhausted 
phenotype and can 
produce cytokines 
supporting cancer 
growth 
- unestablished, 
equivocal role in 
tumor progression 
and metastasis 
- recognize tumor neoantigens  
- decelerate tumor growth in 
experimental model of 
cancer development 
- exhibit cytotoxicity against 
cancer cells in experimental 
settings 
- deleterious role in lung 
cancer? 
- direct and indirect 
immunosurveillance 
[15,32,47,58–
61] 
Role in 
hematological 
malignancies 
- immune checkpoint 
therapy counters 
MAIT cell deficiency 
in peripheral blood  
- direct cytotoxicity 
against multiple 
myeloma cells 
expressing MR1 
molecule in 
experimental 
settings 
- effective coaddition of iNKT 
cell stimulation to standard 
therapies in multiple 
myeloma and lymphomas 
[47,62–64] 
Dependence on 
microbiome 
Commensal microbiota 
required for MAIT cell 
maturation, activation of 
MAIT cells by microbial 
antigens 
(immature) iNKT cell numbers 
increase in germ-free mice, 
microbial antigens induce 
proinflammatory responses in 
iNKT cells 
[65,66] 
MAIT, mucosal-associated invariant T cells; iNKT, invariant natural killer T cells; TCR, T cell receptor; 
MR1, major histocompatibility complex class I-like protein; 5-OP-RU, 5-(2-oxopropylideneamino)-6-
D-ribitylaminouracil; 5-OE-RU, 5-(2-oxoethylideneamino)-6-D- ribitylaminouracil; α- GalCer, alpha-
Galactosylceramide; β-GlcCer, beta-glucosylceramide; Ac-6-FP, acetyl-6-formylpterin; PLZF, 
promyelocytic leukaemia zinc finger protein; RORγt, Retineic-acid-receptor-related orphan nuclear 
receptor gamma; T-bet, T-box transcription factor; GATA3, GATA binding protein 3; IL-7R, 
interleukin 7 receptor; CRTAM, cytotoxic and regulatory T cell molecule. 
3. MAIT Cells in Immune-Mediated Diseases 
Despite the broad heterogeneity of autoimmune and autoinflammatory diseases’ etiology, 
several recurrent observations on phenotypical and functional alterations of MAIT cells were made. 
In the peripheral blood of patients diagnosed with different disorders {systemic lupus erythematosus 
[67], ankylosing spondylitis [68], rheumatoid arthritis (RA) [69], vasculitis [70], systemic sclerosis [71], 
primary Sjögren syndrome (pSS) [72], primary sclerosing cholangitis (PSC) [73] and inflammatory 
bowel disease [31, 74]}, MAIT cells were shown to be significantly reduced. Of note, in some diseases, 
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iNKT cell counts are also decreased, pointing towards a functional interdependence between the 
populations in these diseases. In Lupus, a strong positive correlation between MAIT cell deficiency 
and disease activity was seen. Interestingly, not all MAIT cell subsets decreased to the same extent. 
For instance, an alteration in population composition in terms of the expression of CD4 and CD8 
coreceptors was observed in RA and pSS patients [72]. Differences in cytokine secretion profiles of 
peripheral blood MAIT cells were seen between autoimmune disease patients and matched healthy 
controls, which could reflect shifts in MAIT cell subsets upon disease development and/or 
progression. Latest research confirmed that MAIT cell activity is highly dependent on early-life 
environmental stimulation, including host–microbiome interactions, factors largely postulated to be 
of relevance to autoimmune disease pathogenesis. 
MAIT cells have also been found to infiltrate the tissues affected in the course of immune-
mediated diseases. In the synovium of RA and spondyloarthritis patients, MAIT cells accumulate 
and have distinctively downregulated activation markers, which is consistent with 
hyporesponsiveness to potent microbial stimuli [69]. The same functional exhaustion was described 
for MAIT cells infiltrating biliary ducts in primary sclerosing cholangitis, salivary glands of pSS 
patients [71], and intestinal lesions in the course of inflammatory bowel disease [31,74], showing 
increased cell turnover (measured by Ki67 stainings) in the latter condition. This suggests that the 
infiltrating MAIT cells are chronically stimulated, possibly both by a multitude of locally produced 
inflammatory cytokines and/or TCR-mediated signals. Indeed, loss of mucosal barriers integrity—
commonly associated with autoimmune diseases—may result in an increased exposure to microbial 
stimuli, which might lead to upheld activation and, ultimately, exhaustion of MAIT cells. In 
conclusion, these findings suggest a significant role of MAIT cells in the course of autoimmune 
pathologies. 
4. MAIT Cells in Graft-Versus-Host Disease 
The role of MAIT cells in the reconstitution of the immune repertoire after allogenic 
hematopoietic stem cell transplantation has been investigated in several studies. The recovery of 
MAIT cells in the graft recipient was found to be dependent on donor cells transferred directly or as 
precursor cells, and their proliferation correlated with the abundance of intestinal commensal 
bacterial species [75]. Reconstituting MAIT cells were functionally impaired and sensitive to 
chemotherapeutics [76]. Because MAIT cells preferentially localize in the organs affected by graft-
versus-host disease (GvHD), their role in this immune phenomenon was studied. An increase in the 
peripheral blood MAIT cells early after stem cell transplantation was associated with reduced risk of 
GvHD development [75,77]. The authors suggested that this could be due to MAIT cell potency of 
suppressing CD4+ T cell proliferation. Studies in mice reported that deficiency in MAIT cells 
aggravates GvHD and reduces survival rates. Further experiments showed that MAIT cell depletion 
allowed for proliferation of alloreactive donor T cells, especially in the colon [78]. The effect is thought 
to be IL-17 dependent, having an effect on the microbiota composition, alloantigen presentation, and 
maintenance of the intestinal barrier integrity. This is in line with previous finding on an IL-17-
producing T cell population in GvHD [79]. Of note, granulocyte colony-stimulating factor (G-CDF), 
routinely used for stem cell mobilization in donors, was found to promote IL-17 secretion by 
circulating donor CD8+ MAIT cells [80]. This has to be taken in consideration given that IL-17 has a 
dual role in intestinal homeostasis [81]. 
5. MAIT Cells in Malignant Diseases 
Recent research sheds light on the major role of microbiome in the development of the host’s 
immune system as well as in infectious, inflammatory, and malignant diseases. Moreover, infectious 
agents are estimated to trigger the development of 20% of cancers worldwide [82]. Given their 
abundance in humans, the ability to rapidly secrete a plethora of inflammation mediators, and the 
link with microbiota, the investigation of MAIT cells is gaining interest in the oncology field, and the 
distinctive characteristics of MR1 restricted antigen presentation further urge researchers to 
determine their functional role in tumorigenesis and cancer immunity. Since the first discovery of 
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riboflavin-related antigens as MAIT cells-activating MR1 ligands, the list of other MR1 targets 
expanded significantly. Folate-derivatives formylpterins were ascertained as MAIT cells inhibitors. 
Non-vitamin B-derived ligands were found to bind to MR1 as well, including pharmacological agents 
and their metabolites: diclofenac, 3-formylsalicylic acid, and intermediate methotrexate metabolite 
[83]. Thus far, no endogenous ligands have been identified, but their existence is supported by the 
persistence of MAIT cells selection in the thymus of germ-free mice and the minimal surface 
expression of MR1 protein by certain human cell lines [2,18]. The identification of endogenous MR1 
ligands would greatly augment our understanding of the role of MAIT cells in autoimmune diseases 
and tumor immunity. Concurrence of immune phenomena among autoimmune and malignant 
diseases often allows for approximate translation of findings, and this paradigm also applies to MAIT 
cell biology. The rapidly growing understanding of their function and the promise of its modulation 
might potentially put MAIT cells at the center of modern immunotherapy development. 
5.1. Hepatic Malignancies 
The liver is an immunologically intriguing organ continuously exposed to microbial and food 
antigens carried by the portal vein circulation and densely populated by unusual immune cells, 
particularly MAIT and iNKT cells [84,85]. Despite this notable immune surveillance, malignant 
transformation is a relatively common complication of chronic liver inflammation in both 
autoimmune disorders and persistent viral infections. Therefore, elucidating the role of MAIT cells 
in different chronic liver diseases is crucial in understanding processes leading from sustained 
inflammation to hepatic cancer development (Figure 2). 
In hepatocellular carcinoma (HCC) patients, peripheral blood MAIT cells are numerically and 
functionally depleted [86]. Similar discoveries were made in terms of several chronic inflammatory 
conditions that are associated with an increased risk of malignant transformation in the liver, namely 
hepatitis C virus (HCV) infection [87], primary biliary cholangitis [88], and alcoholic and non-
alcoholic fatty liver disease [89]. The degree of MAIT cell deficiency corresponded with disease 
progression, measured as HCC advancement, extent of liver fibrosis, or serum level of liver damage 
markers. The remaining circulating MAIT cells showed an upregulated expression of activation and 
exhaustion markers: immune checkpoint molecules such as PD-1 in HCC, and CD38, CD39, CD69, 
and HLA-DR in autoimmune liver disease and non-alcoholic fatty liver disease. This was reflected 
by decreased production of IFN-γ. Interestingly, peripheral blood MAIT cells from patients with 
chronic liver inflammation selectively maintained some of their secretory function. While incapable 
of upregulating granzyme production upon stimulation, MAIT cells were still able to produce IL-17 
[90]. This preferential maintenance of IL-17 production in exhausted MAIT cells could be significant 
in the context of cancer development and liver fibrosis [91,92]. MAIT cells were recently shown to 
contribute to liver fibrosis progression by two mechanisms: through activation of hepatic stellate cells 
via IL-17 [90] and through MR1 signaling-dependent enhancement of hepatic myofibroblast 
proliferation [93]. 
MAIT cells express a repertoire of chemokine receptors associated with liver (and mucosal 
tissue) homing capacities. The peripheral blood MAIT cells of HCC patients expressed CCR6, CXCR6, 
and CCR9, but these molecules were decreased on their liver cell counterparts and were even further 
reduced near the tumor burden [86]. The density of MAIT cells in the liver was significantly decreased 
in the tumor compartment compared to peritumor tissue and non-affected liver [94]. A transcriptomic 
analysis of MAIT cells in healthy liver tissue, peritumor, and tumor microenvironment revealed 
striking phenotypical differences. The differentially regulated genes were mostly related to 
metabolism, cytokine secretion, and cytolysis, pointing towards the capacity of tumor 
microenvironment to modulate MAIT cell metabolism and effector function [86]. Studies of MAIT 
cells in hepatic metastases are in line with these findings, showing that MAIT cells could infiltrate 
metastatic foci but became dysfunctional [95]. Tumor-infiltrating liver MAIT cells showing an 
exhausted memory effector phenotype accordingly failed to produce IFNγ and cytolytic molecules. 
Moreover, they produced IL-8, a cytokine implicated in tumor angiogenesis and progression, which 
might reflect shifts towards tumor-supportive MAIT cells phenotypes at metastatic sites [86]. 
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Persistent infections with hepatotropic viruses are the leading cause of HCC [96], and a drop in 
circulating MAIT cells was observed for both HCV and hepatitis B virus (HBV) patients [97,98]. The 
depletion correlated with signs of immune senescence and exhaustion of conventional T cell 
populations, pointing towards a close relationship between the function of MAIT cells and the 
immune environment. Strikingly, MAIT cells of chronic HBV patients frequently expressed the 
surface molecule CD57 [99], which is associated with immunosenescence [100]. Furthermore, they 
expressed upregulated levels of exhaustion markers PD-1 and CTLA-4, which reflected functional 
impairment of perforin, granzyme, and IFN-γ production [99]. Superinfection with hepatitis D virus 
is known to exacerbate chronic HBV-related hepatitis and increase the risk of developing cancer [101]. 
Recently, immune alterations in hepatitis D virus patients were shown with a dramatic depletion of 
circulating MAIT cells and functional impairment of the liver-resident subset, particularly in 
response to MR1-specific ligands [102]. It might be possible that the loss of a functional (protective) 
MAIT cell population occurs upon progression of hepatotropic virus-related carcinogenesis. 
5.2. Mucosal-Associated Cancers 
In studies that included patients with various malignant tumors, a deficiency in circulating 
MAIT cells was observed only for mucosal-associated cancers, namely gastric, colon [58], and lung 
cancer[59]. Moreover, this MAIT cell depletion correlated with the stage of the disease defined by the 
N parameter, the levels of serum carcinoembryonic antigen (CEA), and the patient hemoglobin. 
Furthermore, the composition of MAIT cell subsets in the peripheral blood of colon cancer patients 
were different from the matched healthy control group [59]. The subset of CD8+ memory MAIT cells 
was particularly reduced [58]. 
In colon cancer patients, MAIT cells were found to infiltrate tumor tissue [32,58,59,103,104]. This 
is in accordance with the pattern of tissue-homing chemokine receptors of the MAIT cells isolated 
from the peripheral blood and the intestinal mucosa of colon cancer [59]. qPCR analyses showed that 
their absence correlated with IFN-γ (decreased) and IL-17A (increased) detection in tumor tissues. 
Accordingly, circulating MAIT cells of colon cancer patients produced higher levels of IL-17 
compared to the healthy control group [58], suggesting a shift towards Th17 phenotype in MAIT cells 
of colon cancer patients. In vitro studies on peripheral blood MAIT cells isolated from healthy 
individuals demonstrated that they possess lymphokine-activated killer activity and direct 
cytotoxicity to myelogenous leukemia cells after activation [59]. Coincubation assays with colorectal 
carcinoma cells further showed that activated MAIT cells can induce cell cycle arrest in malignant 
cells in a contact- and dose-dependent manner. Moreover, similar coculture experiments led to a 
decreased viability of an esophageal adenocarcinoma cell line [105]. These findings prove that MAIT 
cells are equipped and have the potential to oppose carcinogenesis, at least in vitro. The degree of 
MAIT cell infiltration into the malignant tissue, however, correlated with disease advancement [58] 
and poor prognosis [103]. The functional assessment of tumor-infiltrating MAIT cells revealed an 
enrichment in IL-17-producing and a depletion in IFN-γ-producing subpopulations compared to the 
unaffected colonic tissue of the same patients [58]. Furthermore, chronic stimulation of MAIT cells 
results in an increase of IL-13 gene expression and consequent IL-13 production [32]. This finding is 
particularly interesting in the context of high expression of IL-13 receptor on precancerous intestinal 
polyps and colorectal cancer tissue [32]. MAIT cell immune exhaustion is likely dependent on soluble 
mediators released by the tumor mass, as stimulating peripheral blood mononuclear cells with tumor 
conditioned medium resulted in a decrease in Th1 cytokines [105]. Determining the exact factors 
causing a switch from anti-tumor to tumor-favorable MAIT cell phenotype would be key for the 
design of future immunotherapeutics. 
5.3. Non Mucosal-Associated Solid Tumors 
The functional impact on MAIT cells, and hence their anti-tumor activity, seems to be slightly 
different in the context of non-mucosal associated solid tumors (such as brain, kidney, thyroid, and 
breast cancer). Peripheral blood MAIT frequencies were higher in non-mucosal associated solid 
tumors [59]. An early study of invariant TCRs expression in solid brain and kidney tumor tissues 
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revealed clonal expansion of MAIT cells paired with iNKT cell infiltration and correlating with 
proinflammatory cytokines expression [106]. 
 
Figure 2. MAIT cells in solid tumors. The frequency of MAIT cells in the peripheral blood negatively 
reflects the progression of the studied malignant diseases. The reduction in circulating MAIT cells 
coincided with the overexpression of immune exhaustion markers on their surface. By their tissue-
homing properties, MAIT cells actively infiltrate solid tumors and metastatic lesions. However, MAIT 
cells isolated from the tumor microenvironment seem functionally altered, as they show a reduced 
capacity to produce granzyme, IFNγ, and TNFα and more IL-17, IL-8, and IL-13. MAIT, mucosal-
associated invariant T cell; IFNγ, interferon gamma; TNFα, tumor necrosis factor alpha, IL-17, 
interleukin 17; CCR6, C-C chemokine receptor 6; CXCR6, C-X-C motif chemokine receptor 6; CCR9, 
C-C chemokine receptor type 9. 
5.4. Haematological Malignancies (Multiple Myeloma) 
To date, little is known about MAIT cell function in hematological malignancies. Multiple 
myeloma (MM) cell lines were shown to express the MR1 protein, capable of binding and presenting 
vitamin B metabolites to MAIT cells. In response, MAIT cells isolated from healthy middle-aged 
donors specifically lysed these myeloma cells in vitro, with efficiency and kinetics similar to natural 
killer (NK) cells [62]. Nevertheless, MAIT cell frequencies were greatly diminished in untreated MM 
patients and particularly the CD8+ and the CD8-CD4- subsets were affected [47]. Effector functions 
of MM patients MAIT cells were further decreased, with fewer IFNγ- (and TNFα)-producing cells, 
although IFNγ-producing capacity seemed restored in relapsed/refractory MM patient samples 
[47,62]. Favreau et al. also showed increased PD-1 levels on both circulating MAIT and iNKT cells 
[47]. In vitro blockade of the PD-1 receptor resulted in restoration of MAIT cell function and enabled 
reciprocal activation of the two innate-like cell populations [47]. These results point towards the 
potential of MAIT cells as immunotherapeutic target in MM, both directly for their antitumor 
immunity by direct cytolytic activity and indirectly by stimulating a range of innate and adaptive 
immune cells. 
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5.5. A Role for MAIT Cells in Cancer Immunotherapy? 
The tumor microenvironment is created by the malignant cells as well as the infiltrating immune 
cells, together generating complex and multidirectional stimuli. Because of their secretory repertoire 
and the ability to activate and steer other immune cells, MAIT and iNKT cells are postulated to 
strongly contribute to the tumor immunosurveillance. Interestingly, iNKT cells have been explored 
as targets in cancer therapy, primarily because of their strong anti-tumor capacities, their ability to 
functionally modulate other immune cells, and the expected lack of allogeneic (anti-host MHC) 
responses—features they share with MAIT cells. Consequently, similar strategies might be applied 
with regard to MAIT cells and, conceivably, valuable lessons can be learned from published iNKT 
cell-based trials. The use of α-GalCer and other glycolipids to activate iNKT cells has engendered 
preclinical success in mice, leading to multiple clinical trials with small but significant cohorts of 
patients with adenocarcinoma (AC), large-cell carcinoma (LCC), multiple myeloma (MM), non-small-
cell lung cancer (NSCLC), renal cell carcinoma (RCC), or squamous cell carcinoma (SCC) [107]. 
Although the translation of these preclinical benefits into clinical trials is associated with some 
challenges, they provided encouraging results with tumor stabilization and, in some cases, tumor 
regression. Similarly, MAIT cell activation strategies with agonist ligands such as VitB ligands might 
be of potential interest. Notably, 5-OP-RU seems to mainly influence MAIT17 cell thymic 
development [18], which could be of concern given the cancer-promoting activity of MAIT cell-
secreted IL-17. A broader range of molecules, including drugs and drug-like molecules and 
potentially (still to be identified) endogenous ligands could be added to these attempts [83]. Whether 
MAIT cells can recognize tumor neoantigens in the context of MR1 presentation and whether they 
can respond to tumor cells are important questions. In this regard, a recent in vivo study by Yan et 
al. unexpectedly showed that MAIT cells were found to promote cancer metastasis by suppressing T 
and/or NK cells (which was partly IL-17 dependent) after interaction with MR1 molecules expressed 
on tumor cells and pre-treatment of tumor cells with 5-OP-RU increased lung metastases [9]. These 
data suggest that blocking MR1 (or providing inhibitory MAIT ligands) may represent an interesting 
strategy for cancer immunotherapy [9]. In contrast, another recent report shows that a human T cell 
clone that recognizes an MR1 restricted nonbacterial antigen (potentially a cancer-specific or 
associated metabolite) mediates potent lysis of different cancer cell types [108]. In addition, other 
atypical MR1 restricted T cells (not responding to 5-OP-RU) have been described [16,19,109], some 
reacting towards tumor cells such as “MR1T cells” [8], but more research is needed to unravel the 
precise nature and function of these cells. These findings seem to be related to some extent to findings 
in the NKT cell field, where CD1d restricted type 2 NKT cells that—in contrast to iNKT cells (also 
called type 1 NKT cells), show a diverse (broad) TCR repertoire and ligand recognition (not 
responding to αGalCer)—have been associated with the regulation and the inhibition of tumor 
immunity in murine tumor models and patients (reviewed in [117]). Altogether, this warrants further 
investigation into the role and the antigen reactivity of diverse MAIT (-like) cell subsets in the context 
of anti-tumor responses. 
An important hurdle for targeting iNKT cells is their low and variable frequency in peripheral 
circulation. MAIT cells are far more prevalent in humans than iNKT cells, although they might also 
be reduced under malignant conditions. Adoptive iNKT cell therapies making use of chimeric 
antigen receptors (CAR-iNKT) engineering can circumvent this issue and seem to provide promising 
results with prolonged in vivo persistence and superior target-specific killing activity in preclinical 
studies [64,110,111]. Given their restricted TCR usage, this strategy can also be explored for MAIT 
cells (MAIT-CAR). Another important obstacle is the observation of functional exhaustion of iNKT, 
which has also been shown for MAIT cells [112,113]. For instance, administration of soluble iNKT 
ligands have been linked to the upregulation of inhibitory co-stimulatory molecules such as PD-1 
[114]. A combination therapy with a MAIT cell stimulus and an immune checkpoint inhibitor might 
therefore be needed for optimal and long-term antitumor responses [47]. Development of diagnostic 
tools that enable appropriate patient stratification and selection will be the main challenge. Together 
with response to treatment biomarker identification, these will allow one to maximize treatment 
efficacy and reduce the socio-economic burden currently associated with immunotherapies. 
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6. Conclusions 
MAIT cells are a unique, evolutionarily conserved population bridging innate and adaptive 
immunity. The development of MAIT cells is strongly dependent on commensal microbiota stimuli; 
accordingly, the population is enriched at mucosal sites [3]. This underlies a reciprocal interaction, as 
MAIT cells are capable of shaping the microbial population as determined in MR1 deficient mice [78]. 
They recognize a range of pathogens upon a shared metabolic signature, and their TCR is restricted 
to the recognition of non-protein antigens presented by non-polymorphic MR1 proteins. Recent 
studies have shed light on fascinating features of MAIT cell biology and their functional regulation. 
Depending on the co-stimulating factors and the inflammatory environment, MAIT cells can exert 
different roles [29], which is of relevance in disease context. Moreover, via direct contact and copious 
production of soluble mediators, MAIT cells further influence other cell populations and orchestrate 
the immune response. 
MAIT cells have been linked to a variety of diseases and pathological conditions, including 
infectious and autoimmune disorders and cancer. Studies on MAIT cell function in autoimmune 
diseases could be of particular relevance to cancer research, since multiple paraneoplastic syndromes 
resemble the symptoms of autoimmune diseases. Furthermore, malignant transformation is a late but 
frequent complication of many autoimmune diseases. For example, lifetime incidence of 
cholangiocarcinoma is as high as 20% among primary sclerosing cholangitis patients, and the 
presence of abdominal malignancies has been strongly linked to the mortality rate in these patients 
[115]. pSS disease is associated with a 16-fold increased risk of developing non-Hodgkin’s 
lymphomas [116,117]. Sarcoidosis, perceived as a manifestation of chronic inflammation, is also 
associated with increased risk of cancer [118]. Persistent inflammation causes DNA damage and 
increases tissues’ susceptibility to oncogenesis [119]. MAIT cells were found to infiltrate chronically 
inflamed tissues, in which they displayed a hyperactivated and exhausted phenotype [120]. 
However, their abundance in solid tumors and peritumor zones is much lower compared to the 
healthy tissue. Tumor-infiltrating MAIT cells are functionally distorted, which is reflected by the 
production of potentially tumor-promoting cytokines. Singular discrepancies in the results of studies 
on MAIT cells in cancer might be the consequence of large interindividual differences, disease 
heterogeneity, small study populations, and MAIT cell identification and characterization 
techniques. MR1 molecule tetramers only recently became commercially available and, in the 
majority of thus-far published studies, MAIT cells were identified as TCRVα7.2 and CD161 positive 
cells. Therefore, future work with these advanced tools and new research techniques—such as single-
cell RNA sequencing—will shed further light on the phenotype and the function of MAIT and other 
MR1 restricted cells in the context of malignancies and their potential as targets in immunotherapy. 
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